22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › AbCellera Biologics Inc. › 2024-2025

AbCellera Biologics Inc. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and AbCellera Biologics Inc.’s Form 8-K, filed June 13, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 6Reported items
  • 102Asset managers, any item
  • 186Fund votes
  • June 12, 2025Meeting date

Results at a glance

Meeting of June 12, 2025: 4 items on AbCellera Biologics Inc.’s Form 8-K, filed June 13, 2025: 2 approved · 2 passed (calculated).

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore AbCellera Biologics Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by AbCellera Biologics Inc.

These tallies are AbCellera Biologics Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 13, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

AbCellera Biologics Inc. — official shareholder meeting results, meeting held June 12, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Carl L. G. Hansen, Ph.D. 141,233,414444,2656,760,498 ---- 99.7%Passed (calculated)—
Elect Director: Michael Hayden, MBCHB (M.D.), Ph.D. 121,224,143417,79426,796,240 ---- 99.7%Passed (calculated)—
2. Proposal 2 183,078,982678,941241,151 ---- 99.6%Approved—
3. Proposal 3 131,605,59516,469,354363,228 ---- 89%Approved—

Source: AbCellera Biologics Inc., Form 8-K, filed with the SEC on June 13, 2025 — read the filing on EDGAR.

How asset managers voted at the AbCellera Biologics Inc. 2024-2025 meeting

102 asset managers disclosed a vote on at least one AbCellera Biologics Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of AbCellera Biologics Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Carl L. G. Hansen, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 141,233,414AGAINST: 444,265
Details: description as filed, official tally, votes by 13 asset managers

Description as filed by funds: To elect two class II directors to our Board of Directors, to serve until the 2028 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Carl L.G. Hansen

AbCellera Biologics Inc.’s own tally for this item (“Elect Director: Carl L. G. Hansen, Ph.D.”): 141,233,414 for, 444,265 against, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 13 asset managers below reported 14,428,367 for, 6,133,665 withheld.

FORWITHHOLD
FOR: 14,428,367WITHHOLD: 6,133,665
Largest asset managers voting on “To elect two class II directors to our Board of Directors, to serve until the 2028 Annual Meeting of Sharehold” at AbCellera Biologics Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group13,361,0960 00For
Virtus00 06,133,665Withhold
Vanguard401,3060 00For
BlackRock188,6230 00For
Federated Hermes150,0000 00For
Listed Funds Trust112,5430 00For
American Century84,6330 00For
Blackstone Alternative Investment Funds39,0000 00For
State Street30,3430 00For
ETFis Series Trust I21,6430 00For
MASTER INVESTMENT PORTFOLIO18,2570 00For
ProShares12,0400 00For
Fidelity8,8830 00For

Elect Director: Michael Hayden, MBCHB (M.D.), Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 121,224,143AGAINST: 417,794
Details: description as filed, official tally, votes by 13 asset managers

Description as filed by funds: To elect two class II directors to our Board of Directors, to serve until the 2028 Annual Meeting of Shareholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: Michael Hayden

AbCellera Biologics Inc.’s own tally for this item (“Elect Director: Michael Hayden, MBCHB (M.D.), Ph.D.”): 121,224,143 for, 417,794 against, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 13 asset managers below reported 14,128,165 for, 6,433,867 withheld.

FORWITHHOLD
FOR: 14,128,165WITHHOLD: 6,433,867
Largest asset managers voting on “To elect two class II directors to our Board of Directors, to serve until the 2028 Annual Meeting of Sharehold” at AbCellera Biologics Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group13,361,0960 00For
Virtus00 06,133,665Withhold
Vanguard401,3060 00For
BlackRock188,6230 00For
Federated Hermes150,0000 00For
Listed Funds Trust00 0112,543Withhold
American Century00 084,633Withhold
Blackstone Alternative Investment Funds00 039,000Withhold
State Street00 030,343Withhold
ETFis Series Trust I00 021,643Withhold
MASTER INVESTMENT PORTFOLIO18,2570 00For
ProShares00 012,040Withhold
Fidelity8,8830 00For

To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, or Say-on-Pay.

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 8 wordings of this item as funds reported it.

55% Fund and manager reports combined; may count the same shares twice · no official result

FORAGAINST
Details: votes by 97 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 13 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, or Sa” at AbCellera Biologics Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group013,361,096 00Against
Virtus6,133,6650 00For
Vanguard401,3060 00For
BlackRock188,6230 00For
Federated Hermes150,0000 00For
Listed Funds Trust112,5430 00For
American Century84,6330 00For
Blackstone Alternative Investment Funds39,0000 00For
State Street30,3430 00For
ETFis Series Trust I21,6430 00For
MASTER INVESTMENT PORTFOLIO18,2570 00For
ProShares12,0400 00For
Fidelity8,8830 00For

Fund voting reports, all 13 managers: 7,200,936 for, 13,361,096 against.

Institutional-manager reports: 88 asset managers voting on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, or Sa” at AbCellera Biologics Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group013,361,296 00Against
BAILLIE GIFFORD & CO LTD4,746,4170 00For
Voya4,490,5200 00For
ORBIMED ADVISORS LLC4,180,7680 00For
ArrowMark Colorado Holdings LLC4,105,0950 00For
NICOLA WEALTH MANAGEMENT LTD.1,400,3500 00For
Lazard1,136,6530 00For
Novo Holdings A/S1,126,9150 00For
BAILLIE GIFFORD OVERSEAS LTD1,027,6860 00For
BlackRock884,4840 00For
UI BVK Kapitalverwaltungsgesellschaft mbH686,5730 00For
UBS0612,878 00Against
Polar Asset Management Partners Inc.459,4000 00For
Renaissance387,5480 00For
Citadel306,2800 00For
Federated Hermes150,000123,308 00Mixed
PIER 88 INVESTMENT PARTNERS LLC243,7900 00For
Guardian Partners Inc.200,4500 00For
Mediolanum International Funds Ltd178,3370 00For
Allianz123,0770 00For
American Century84,6330 00For
PNC BANK, NATIONAL ASSOCIATION80,0000 00For
Northern Trust75,7820 00For
Two Sigma70,1190 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC64,2320 00For

Institutional-manager reports, all 88 managers: 26,631,485 for, 14,109,475 against. Showing the 25 largest; every one is in the interactive database (link above).

Advisory Vote to Ratify Named Executive Officers' Compensation

No official matchCOMPENSATION

100% of fund votes cast · no official result

FOR
Details: votes by 3 asset managers

The 3 asset managers below reported 9,803,037 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 9,803,037
Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at AbCellera Biologics Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
TD ASSET MANAGEMENT INC9,399,4860 00For
Desjardins Global Asset Management Inc.380,1110 00For
TD Waterhouse Canada Inc.23,4400 00For

14A Executive Compensation

No official matchSECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

100% of fund votes cast · no official result

FOR
Details: votes by 2 asset managers

The 2 asset managers below reported 33,872 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 33,872
Largest asset managers voting on “14A Executive Compensation” at AbCellera Biologics Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Green Alpha Advisors, LLC33,8620 00For
Focus Partners Wealth100 00For

To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending…

No official matchAUDIT-RELATED

Combines 2 wordings of this item as funds reported it.

100% of fund votes cast · no official result

FOR
Details: description as filed, votes by 13 asset managers

Description as filed by funds: To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025;

The 13 asset managers below reported 20,562,032 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 20,562,032
Largest asset managers voting on “To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year” at AbCellera Biologics Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Capital Group13,361,0960 00For
Virtus6,133,6650 00For
Vanguard401,3060 00For
BlackRock188,6230 00For
Federated Hermes150,0000 00For
Listed Funds Trust112,5430 00For
American Century84,6330 00For
Blackstone Alternative Investment Funds39,0000 00For
State Street30,3430 00For
ETFis Series Trust I21,6430 00For
MASTER INVESTMENT PORTFOLIO18,2570 00For
ProShares12,0400 00For
Fidelity8,8830 00For

Largest AbCellera Biologics Inc. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 298,484,664 shares outstanding at the time of that meeting.

Fund voting reports: top AbCellera Biologics Inc. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive…”, 2024-2025
#Asset manager % of shares outstanding
1Capital Group 4.48%
2Virtus 2.05%
3Vanguard 0.13%
4BlackRock 0.06%
5Federated Hermes 0.05%
6Listed Funds Trust 0.04%
7American Century 0.03%
8Blackstone Alternative Investment Funds 0.01%
9State Street 0.01%
10ETFis Series Trust I <0.01%
Institutional-manager reports: top AbCellera Biologics Inc. shareholders by shares voted on “To approve, on a non-binding advisory basis, the compensation of the Company's named executive…”, 2024-2025
#Asset manager % of shares outstanding
1Capital Group 4.48%
2BAILLIE GIFFORD & CO LTD 1.59%
3Voya 1.50%
4ORBIMED ADVISORS LLC 1.40%
5ArrowMark Colorado Holdings LLC 1.38%
6NICOLA WEALTH MANAGEMENT LTD. 0.47%
7Lazard 0.38%
8Novo Holdings A/S 0.38%
9BAILLIE GIFFORD OVERSEAS LTD 0.34%
10BlackRock 0.30%

Reported AbCellera Biologics Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

AbCellera Biologics Inc. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Carl L.G. Hansen, Ph.D.63,366,108 21.23%Proxy statement (DEF 14A), proxy filed April 29, 2025
Thermopylae Holdings Ltd.56,143,640 18.81%Proxy statement (DEF 14A), proxy filed April 29, 2025
Baker Bros. Advisors LP27,525,640 9.22%Proxy statement (DEF 14A), proxy filed April 29, 2025
Véronique Lecault, Ph.D.12,670,618 4.24%Proxy statement (DEF 14A), proxy filed April 29, 2025
Andrew Booth6,092,875 2.04%Proxy statement (DEF 14A), proxy filed April 29, 2025
BlackRock3,576,208 1.20%Form 13F, quarter ended March 31, 2025
Two Sigma3,126,789 1.05%Form 13F, quarter ended March 31, 2025
Renaissance Technologies2,894,029 0.97%Form 13F, quarter ended March 31, 2025
Tryn Stimart2,676,257 0.90%Proxy statement (DEF 14A), proxy filed April 29, 2025
Citadel Advisors2,007,174 0.67%Form 13F, quarter ended March 31, 2025

Percentages above are of 298,484,664 shares outstanding, as reported by AbCellera Biologics Inc. on its Form 10-Q dated May 5, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At AbCellera Biologics Inc.'s shareholder meeting held June 12, 2025, in the 2024-2025 proxy season, 102 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 186 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. AbCellera Biologics Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, on a non-binding advisory basis, the compensation of the Company's named executive… — the reporting funds and managers cast 55% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from AbCellera Biologics Inc.’s 10-Q dated May 5, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

AbCellera Biologics Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “AbCellera Biologics (ABCL) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/abcellera-biologics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.